FindTrial
Sign In

Study on the Therapeutic Effect and Related Influencing Factors of Anti-VEGF Therapy for PCV Evaluated by Wide-field OCTA

Based on wide-field OCTA to evaluate changes in the vitreoretinal interface and vascular factors in PCV patients before and after anti-VEGF therapy, and their relationship with prognosis.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125585
Enrollment
Unknown
Registered
2026-05-28
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polypoidal choroidal vasculopathy

Interventions

PCV with vitreoretinal interface abnormality:None
PCV without vitreoretinal interface abnormality:None

Sponsors

The Zhongshan Ophthalmic Center,Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adult patients (>=18 years old) with a diagnosis of polypoidal choroidal vasculopathy (PCV) confirmed by ICGA, regardless of gender. 2. Patients should be treatment-naïve for PCV, with no prior treatment for PCV. 3. Patients will receive anti-VEGF therapy with complete regimen, using Conbercept as the therapeutic agent. 4. Patients must be able to undergo OCTA imaging and follow-up, accept wide-field OCTA imaging, agree to complete the required follow-up period (at least 6–12 months), and provide written informed consent. 5. Best-corrected visual acuity (BCVA): 20/400 to 20/40 (Snellen equivalent).

Exclusion criteria

Exclusion criteria: 1. Presence of other severe ocular diseases, including diabetic retinopathy, retinal vein occlusion, uveitis, etc. 2. Opacification of the refractive media precluding adequate OCTA imaging. 3.Intraocular pressure (IOP) > 21 mmHg. 4. Presence of systemic diseases other than diabetes mellitus and essential hypertension that may cause ocular alterations, such as autoimmune diseases, history of major cardiovascular events, neurodegenerative diseases. 5. Poor fixation or inability to cooperate with examinations for other reasons. 6. Long-term use of medications that may induce adverse ocular effects (e.g., oral contraceptives). 7. Any other conditions deemed exclusionary by the investigators.

Design outcomes

Primary

MeasureTime frame
Changes in vitreoretinal interface parameters;—

Secondary

MeasureTime frame
Changes in best-corrected visual acuity (BCVA);OCTA vascular parameters and choroidal/retinal thickness parameters;—

Countries

China

Contacts

Public ContactYing Lin

The Zhongshan Ophthalmic Center, Sun Yat-sen University

linying@gzzoc.com+86 10 63502345

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026